Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9661057 | 0.96 | ADRB1 (0.48) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL875694 | 0.83 | ADRB1 (0.58) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL9621528 | 0.78 | CYP1A2 (0.42) | CYP2D6MEN1CYP1A2KMT2AKDM4E | |
| SCHEMBL11247586 | 0.76 | ADRB1 (0.75) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL6222183 | 0.75 | CARM1 (0.38) | ADRB2KDM4EALDH1A1 | |
| SCHEMBL11250117 | 0.74 | PARP15 (0.46) | ADRB1ADRB2ADRB3 | |
| SCHEMBL11052326 | 0.74 | ALDH1A1 (0.36) | LMNAGAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10528219 | 0.73 | ADRB1 (0.47) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL7289414 | 0.73 | ADRB1 (0.60) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Cicloprolol SCHEMBL9680771 | 0.72 | ADRB1 (0.80) | ADRB1LMNACYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| CN-110831584-A | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2020-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | ADRB1 129/4885LMNA 1421/4885CYP2D6 9/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | ADRB1 208/4885LMNA 2085/4885CYP2D6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.